To include your compound in the COVID-19 Resource Center, submit it here.

Teams identify GFRAL as target for obesity

In three separate papers published in Nature Medicine on Monday, researchers at Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO), Eli Lilly and Co.

Read the full 216 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE